Two Protocols of Letrozole Treatment in Polycystic Ovary Syndrome: Randomized Clinical Trial Publisher



Behrouzilak T¹ ; Hajshafiha M¹ ; Derogar R¹ ; Haghollahi F² Show Affiliations
Source: Journal of Biology and Today's World Published:2017

Abstract

This study is a prospective randomized clinical trial that was conducted on 200 infertile patients with polycystic ovary syndrome (PCOS) in two groups (A and B). Group A (n=100) received Letrozole, 7.5 mg/day for 5 days (short-term group) from day 3 to 7 of menstruation. Group B (n=100) received Letrozole, 5 mg/day for 10 days (long-term group) from day 3 of menstruation. In both groups, the subcutaneous injections of human follicle stimulating hormone (Gonal-F) (75 IU) were applied on days of 5, 7, 9th menstrual cycles. When the follicle size was 18mm or more, human chorionic gonadotropin (hCG) (5000 IU) was injected intramuscular and after 34 to 36 hours, intrauterine insemination (IUI) was performed. The number of follicles and days to reach mature follicle, endometrial thickness, pregnancy and abortion were evaluated. The pregnancy and abortion rate were no differences in two groups. Endometrial thickness and number of mature follicles in group A (short-term) letrozole group are higher than the second group (p<0.05). The results of this small series suggest that short-term with totally low doses of letrozole offers benefit results, regarding number of mature follicles, endometrial thickness and could be the first line treatment for induction of ovulation in PCOS patients. © 2017 Tahereh BehrouziLak et al.